Q2 2026 Earnings

Da Vinci 5 Installed Base - Total

1.7K

(the “EU MDR”) for the da Vinci 5 surgical system for adult and pediatric use in minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic surgical procedures, including urologic, gynecologic, and general laparoscopic procedures, excluding the use of force feedback. We are currently seeking European certification for the use of force feedback in the future. In select geographic markets outside of the U.S. (“OUS”) where we have obtained regulatory clearance, we have launched our da Vinci 5 surgical system. As of June 30, 2026, we have an installed base of 1,710 da Vinci 5 surgical systems, of which 136 systems are located in geographic markets outside of the U.S. Additionally, we extended our fourth-generation platform by adding the da Vinci SP surgical system, commercialized in 2018. The da Vinci SP surgical system accesses the body through a single incision, while the other da Vinci surgical systems access the body through multiple incisions. We are in the early stages of launching our da Vinci SP surgical system, and we have an installed base of 445 da Vinci SP surgical systems as of June 30, 2026. We have received FDA clearance for the da Vinci SP surgical system for urologic, colorectal, general thoracoscopic, and certain transoral procedures. Additionally, the da Vinci SP surgical system has received regulatory clearance in South Korea for a broad set of procedures. The da Vinci SP surgical system has also received regulatory clearance in Japan for the same set of procedures that are currently allowed with the da Vinci Xi surgical system in Japan. In January 2024, the da Vinci SP surgical system received European certification in accordance with the EU MDR for use in endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, and breast surgical procedures, and we are broadening the commercialization of the da Vinci SP surgical system in additional countries and surgical specialties. In August 2024, we obtained regulatory clearance in Taiwan for our da Vinci SP surgical system for use in endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, transanal total mesorectal excision, and breast surgical procedures. We plan to seek FDA clearances for additional indications for the da Vinci SP surgical system and expand the system’s regulatory approvals (including for additional indications) in other OUS geographic markets over time. The success of the da Vinci SP surgical system is dependent on positive experiences and improved clinical outcomes for the procedures for which it has been cleared as well as securing additional clinical clearances.

Da Vinci Installed Base - Asia

2.1K

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci Installed Base - Europe

2.3K

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci Installed Base - Rest of World

659

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci Installed Base - Total

11.7K

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci Installed Base - U.S.

6.6K

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci SP Installed Base

445

(the “EU MDR”) for the da Vinci 5 surgical system for adult and pediatric use in minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic surgical procedures, including urologic, gynecologic, and general laparoscopic procedures, excluding the use of force feedback. We are currently seeking European certification for the use of force feedback in the future. In select geographic markets outside of the U.S. (“OUS”) where we have obtained regulatory clearance, we have launched our da Vinci 5 surgical system. As of June 30, 2026, we have an installed base of 1,710 da Vinci 5 surgical systems, of which 136 systems are located in geographic markets outside of the U.S. Additionally, we extended our fourth-generation platform by adding the da Vinci SP surgical system, commercialized in 2018. The da Vinci SP surgical system accesses the body through a single incision, while the other da Vinci surgical systems access the body through multiple incisions. We are in the early stages of launching our da Vinci SP surgical system, and we have an installed base of 445 da Vinci SP surgical systems as of June 30, 2026. We have received FDA clearance for the da Vinci SP surgical system for urologic, colorectal, general thoracoscopic, and certain transoral procedures. Additionally, the da Vinci SP surgical system has received regulatory clearance in South Korea for a broad set of procedures. The da Vinci SP surgical system has also received regulatory clearance in Japan for the same set of procedures that are currently allowed with the da Vinci Xi surgical system in Japan. In January 2024, the da Vinci SP surgical system received European certification in accordance with the EU MDR for use in endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, and breast surgical procedures, and we are broadening the commercialization of the da Vinci SP surgical system in additional countries and surgical specialties. In August 2024, we obtained regulatory clearance in Taiwan for our da Vinci SP surgical system for use in endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, transanal total mesorectal excision, and breast surgical procedures. We plan to seek FDA clearances for additional indications for the da Vinci SP surgical system and expand the system’s regulatory approvals (including for additional indications) in other OUS geographic markets over time. The success of the da Vinci SP surgical system is dependent on positive experiences and improved clinical outcomes for the procedures for which it has been cleared as well as securing additional clinical clearances.

Ion Installed Base

1.1K

Ion Procedures The adoption of robotic-assisted bronchoscopy using the Ion endoluminal system has the potential to grow if it can offer greater patient value than non-Ion alternatives and competitive total economics for healthcare providers. In the three months ended June 30, 2026, approximately 47,900 biopsy procedures were performed by our customers with Ion systems, compared to approximately 35,300 in the three months ended June 30, 2025. The growth in our overall procedure volume reflects a larger installed base of approximately 1,096 systems, an increase of 21% compared to the installed base of approximately 905 systems as of June 30, 2025. Currently, the vast majority of Ion biopsy procedures are performed in the U.S.

Da Vinci Fixed-Payment Operating-Lease Installed Base

1.5K

The following table summarizes our da Vinci and Ion systems installed base under operating leasing arrangements as of the periods presented (amounts in ones): As of June 30, 2026 | | | June 30, 2025 Da Vinci Surgical System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 1,522 | | | | 1,301 Usage-based operating lease arrangements | | 1,903 | | | | 1,686 Total da Vinci surgical system installed base under operating lease arrangements | | 3,425 | | | | 2,987 Ion System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 110 | | | | 127 Usage-based operating lease arrangements | | 287 | | | | 231 Total Ion system installed base under operating lease arrangements | | 397 | | | | 358

Da Vinci Total Operating-Lease Installed Base

3.4K

The following table summarizes our da Vinci and Ion systems installed base under operating leasing arrangements as of the periods presented (amounts in ones): As of June 30, 2026 | | | June 30, 2025 Da Vinci Surgical System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 1,522 | | | | 1,301 Usage-based operating lease arrangements | | 1,903 | | | | 1,686 Total da Vinci surgical system installed base under operating lease arrangements | | 3,425 | | | | 2,987 Ion System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 110 | | | | 127 Usage-based operating lease arrangements | | 287 | | | | 231 Total Ion system installed base under operating lease arrangements | | 397 | | | | 358

Da Vinci Usage-Based Operating-Lease Installed Base

1.9K

The following table summarizes our da Vinci and Ion systems installed base under operating leasing arrangements as of the periods presented (amounts in ones): As of June 30, 2026 | | | June 30, 2025 Da Vinci Surgical System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 1,522 | | | | 1,301 Usage-based operating lease arrangements | | 1,903 | | | | 1,686 Total da Vinci surgical system installed base under operating lease arrangements | | 3,425 | | | | 2,987 Ion System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 110 | | | | 127 Usage-based operating lease arrangements | | 287 | | | | 231 Total Ion system installed base under operating lease arrangements | | 397 | | | | 358

Ion Fixed-Payment Operating-Lease Installed Base

110

The following table summarizes our da Vinci and Ion systems installed base under operating leasing arrangements as of the periods presented (amounts in ones): As of June 30, 2026 | | | June 30, 2025 Da Vinci Surgical System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 1,522 | | | | 1,301 Usage-based operating lease arrangements | | 1,903 | | | | 1,686 Total da Vinci surgical system installed base under operating lease arrangements | | 3,425 | | | | 2,987 Ion System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 110 | | | | 127 Usage-based operating lease arrangements | | 287 | | | | 231 Total Ion system installed base under operating lease arrangements | | 397 | | | | 358

Ion Total Operating-Lease Installed Base

397

The following table summarizes our da Vinci and Ion systems installed base under operating leasing arrangements as of the periods presented (amounts in ones): As of June 30, 2026 | | | June 30, 2025 Da Vinci Surgical System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 1,522 | | | | 1,301 Usage-based operating lease arrangements | | 1,903 | | | | 1,686 Total da Vinci surgical system installed base under operating lease arrangements | | 3,425 | | | | 2,987 Ion System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 110 | | | | 127 Usage-based operating lease arrangements | | 287 | | | | 231 Total Ion system installed base under operating lease arrangements | | 397 | | | | 358

Ion Usage-Based Operating-Lease Installed Base

287

The following table summarizes our da Vinci and Ion systems installed base under operating leasing arrangements as of the periods presented (amounts in ones): As of June 30, 2026 | | | June 30, 2025 Da Vinci Surgical System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 1,522 | | | | 1,301 Usage-based operating lease arrangements | | 1,903 | | | | 1,686 Total da Vinci surgical system installed base under operating lease arrangements | | 3,425 | | | | 2,987 Ion System Installed Base under Operating Leasing Arrangements Fixed-payment operating lease arrangements | | 110 | | | | 127 Usage-based operating lease arrangements | | 287 | | | | 231 Total Ion system installed base under operating lease arrangements | | 397 | | | | 358

Da Vinci Fixed-Payment Operating-Lease Placements

123

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Da Vinci Operating-Lease Placement Share

54.0%

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Da Vinci Sales-Type Lease Placements

10

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Da Vinci Total Lease Placements

264

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Da Vinci Total Operating-Lease Placements

254

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Da Vinci Usage-Based Operating-Lease Placements

131

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Ion Fixed-Payment Operating-Lease Placements

14

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Ion Operating-Lease Placement Share

56.0%

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Ion Sales-Type Lease Placements

0

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Ion Total Lease Placements

31

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Ion Total Operating-Lease Placements

31

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Ion Usage-Based Operating-Lease Placements

17

Intuitive System Leasing Since 2013, we have entered into sales-type and fixed-payment operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We also enter into usage-based operating lease arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as procedures are performed, offering greater predictability in costs for customers. We believe that all of these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of any of these structures based on customer needs and demand. We include systems placed under fixed-payment and usage-based operating lease arrangements, as well as sales-type lease arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, including usage-based revenue, and Ion system revenue from our da Vinci surgical system average selling price (“ASP”) computations. The following table summarizes our da Vinci and Ion system placements under leasing arrangements for the periods presented (amounts in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 123 | | | | 69 | | | | 248 | | | | 160 Usage-based operating lease arrangements | | 131 | | | | 124 | | | | 249 | | | | 231 Total da Vinci surgical system placements under operating lease arrangements 254 | | | | 193 | | | | 497 | | | | 391 % of Total da Vinci surgical system placements 54% | | | 49% | | | 55% | | | 51% Sales-type lease arrangements | | 10 | | | | 6 | | | | 23 | | | | 16 Total da Vinci surgical system placements under leasing arrangements 264 | | | | 199 | | | | 520 | | | | 407 Ion System Placements under Leasing Arrangements Fixed-payment operating lease arrangements | | 14 | | | | 13 | | | | 36 | | | | 27 Usage-based operating lease arrangements | | 17 | | | | 21 | | | | 31 | | | | 36 Total Ion system placements under operating lease arrangements | | 31 | | | | 34 | | | | 67 | | | | 63 % of Total Ion system placements | | 56% | | | 63% | | | 63% | | | 61% Sales-type lease arrangements | | — | | | | 2 | | | | — | | | | 5 Total Ion system placements under leasing arrangements | | 31 | | | | 36 | | | | 67 | | | | 68

Da Vinci 5 System Placements

246

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci Surgical-System Average Selling Price

$1.6M

The da Vinci surgical system ASP, excluding systems placed under fixed-payment or usage-based operating lease arrangements, Ion systems, and the impact of specified-price trade-in rights, was approximately $1.59 million for the three months ended June 30, 2026, compared to approximately $1.50 million for the three months ended June 30, 2025. The higher second quarter 2026 ASP was largely driven by favorable product mix, including from da Vinci 5 sales, partially offset by an unfavorable geographic mix. ASP fluctuates from period to period based on geographic and product mix, product pricing, systems placed involving trade-ins, and changes in foreign exchange rates. Six Months Ended June 30, 2026 Instruments and accessories revenue increased by 20% to $3.42 billion for the six months ended June 30, 2026, compared to $2.84 billion for the six months ended June 30, 2025. The increase in instruments and accessories revenue was primarily driven by approximately 15% higher da Vinci procedure volume, customer buying patterns, higher da Vinci instruments and accessories revenue per procedure, driven by the da Vinci 5 and da Vinci SP instruments and accessories mix, and foreign currency impacts. The year-to-date 2026 U.S. da Vinci procedure growth was approximately 13%, driven by strong growth in general surgery procedures, most notably cholecystectomy, hernia repair, and appendectomy procedures, as well as growth in gynecological procedures. The number of U.S. da Vinci bariatric procedures performed declined approximately 10% in the first six months of 2026 compared with the first six months of 2025. The year-to-date 2026 OUS da Vinci procedure growth was approximately 20%, driven by growth in general surgery procedures, most notably colorectal, hernia repair, and cholecystectomy procedures; urologic procedures, most notably prostatectomy and partial nephrectomy procedures; and gynecologic procedures, most notably hysterectomy procedures. Geographically, the year-to-date 2026 OUS da Vinci procedure growth was driven by several markets with particular strength in Germany, India, South Korea, Italy, and the United Kingdom. 39 Systems revenue increased by 22% to $1.34 billion for the six months ended June 30, 2026, compared to $1.10 billion for the six months ended June 30, 2025. The higher year-to-date 2026 system revenue was primarily driven by an increase in da Vinci surgical system placements, partially offset by an increase in the proportion of da Vinci surgical system placements under operating leases, higher operating lease revenue, and higher year-to-date 2026 ASPs, driven by an increase in da Vinci 5 system placements. Operating lease revenue, including the contribution from Ion systems, was $512 million for the six months ended June 30, 2026, of which $326 million was variable lease revenue, primarily related to usage-based arrangements, compared to $409 million for the six months ended June 30, 2025, of which $242 million was variable lease revenue, primarily related to usage-based arrangements. Revenue from Lease Buyouts was $108 million for the six months ended June 30, 2026, compared to $69 million for the six months ended June 30, 2025. We expect revenue from Lease Buyouts to fluctuate period to period depending on the timing of when, and if, customers choose to exercise buyout options embedded in their leases. The da Vinci surgical system ASP, excluding systems placed under fixed-payment or usage-based operating lease arrangements, Ion systems, and the impact of specified-price trade-in rights, was approximately $1.66 million for the six months ended June 30, 2026, compared to approximately $1.55 million for the six months ended June 30, 2025. The higher year-to-date 2026 ASP was largely driven by favorable product mix, including from da Vinci 5 system placements, partially offset by an unfavorable geographic mix. ASP fluctuates from period to period based on geographic and product mix, product pricing, systems placed involving trade-ins, and changes in foreign exchange rates.

Da Vinci Procedures - Outside U.S.

337.0K

The following table summarizes the approximate number of procedures performed on da Vinci surgical systems in the U.S. and OUS for the periods presented (number of procedures shown in thousands): Three Months Ended June 30, | | | | | % Change* | | | Six Months Ended June 30, | | | % Change* 2026 | | | 2025 | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 U.S. 552 | | | | 495 | | | | | | 12% | | | 14% | | | 1,081 | | | | 960 | | | | 13% | | | 14% OUS | | | 337 | | | | 280 | | | | | | 20% | | | 23% | | | 656 | | | | 547 | | | | 20% | | | 24% Total Procedures | | | 889 | | | | 775 | | | | | | 15% | | | 17% | | | 1,737 | | | | 1,507 | | | | 15% | | | 17% ___________ * The approximate procedures are rounded to thousands, but the percentage changes are based on unrounded approximate procedures.

Da Vinci Procedures - Total

889.0K

The following table summarizes the approximate number of procedures performed on da Vinci surgical systems in the U.S. and OUS for the periods presented (number of procedures shown in thousands): Three Months Ended June 30, | | | | | % Change* | | | Six Months Ended June 30, | | | % Change* 2026 | | | 2025 | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 U.S. 552 | | | | 495 | | | | | | 12% | | | 14% | | | 1,081 | | | | 960 | | | | 13% | | | 14% OUS | | | 337 | | | | 280 | | | | | | 20% | | | 23% | | | 656 | | | | 547 | | | | 20% | | | 24% Total Procedures | | | 889 | | | | 775 | | | | | | 15% | | | 17% | | | 1,737 | | | | 1,507 | | | | 15% | | | 17% ___________ * The approximate procedures are rounded to thousands, but the percentage changes are based on unrounded approximate procedures.

Da Vinci Procedures - U.S.

552.0K

The following table summarizes the approximate number of procedures performed on da Vinci surgical systems in the U.S. and OUS for the periods presented (number of procedures shown in thousands): Three Months Ended June 30, | | | | | % Change* | | | Six Months Ended June 30, | | | % Change* 2026 | | | 2025 | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 U.S. 552 | | | | 495 | | | | | | 12% | | | 14% | | | 1,081 | | | | 960 | | | | 13% | | | 14% OUS | | | 337 | | | | 280 | | | | | | 20% | | | 23% | | | 656 | | | | 547 | | | | 20% | | | 24% Total Procedures | | | 889 | | | | 775 | | | | | | 15% | | | 17% | | | 1,737 | | | | 1,507 | | | | 15% | | | 17% ___________ * The approximate procedures are rounded to thousands, but the percentage changes are based on unrounded approximate procedures.

Ion Biopsy Procedures

47.9K

Ion Procedures The adoption of robotic-assisted bronchoscopy using the Ion endoluminal system has the potential to grow if it can offer greater patient value than non-Ion alternatives and competitive total economics for healthcare providers. In the three months ended June 30, 2026, approximately 47,900 biopsy procedures were performed by our customers with Ion systems, compared to approximately 35,300 in the three months ended June 30, 2025. The growth in our overall procedure volume reflects a larger installed base of approximately 1,096 systems, an increase of 21% compared to the installed base of approximately 905 systems as of June 30, 2025. Currently, the vast majority of Ion biopsy procedures are performed in the U.S.

Da Vinci Placements Involving Trade-Ins

144

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Da Vinci System Placements - Asia

75

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci System Placements - Europe

79

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci System Placements - Other Geographic Markets

47

During the second quarter of 2026, 468 da Vinci surgical systems were placed compared to 395 systems in the second quarter of 2025. By geography, 267 systems were placed in the U.S., 79 in Europe, 75 in Asia, and 47 in other geographic markets during the second quarter of 2026, compared to 216 systems placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other geographic markets during the second quarter of 2025. The increase in system placements reflects continued demand for additional capacity by our customers as a result of procedure growth as well as increased demand for our da Vinci 5 system, 34 including the impact from customers trading in fourth-generation da Vinci systems. During the second quarter of 2026, we placed 246 da Vinci 5 systems, compared to 180 systems in the second quarter of 2025. As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems compared to approximately 10,488 systems as of June 30, 2025. By geography, 6,615 systems were in the U.S., 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. The incremental system installed base reflects continued procedure growth and further customer validation that robotic-assisted surgery addresses their Quintuple Aim objectives.

Da Vinci System Placements - Outside U.S.

201

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Da Vinci System Placements - Total

468

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Da Vinci System Placements - U.S.

267

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Ion System Placements - Asia

2

During the second quarter of 2026, 55 Ion systems were placed compared to 54 systems in the second quarter of 2025. By geography, 42 systems were placed in the U.S., 9 in Europe, 2 in Asia, and 2 in other geographic markets during the second quarter of 2026, compared to 47 systems placed in the U.S., 3 in Europe, 2 in Asia, and 2 in other geographic markets during the second quarter of 2025. In the U.S., where we estimate that Ion’s penetration of overall lung biopsy procedures has exceeded the halfway point, our customers’ focus has begun to shift from increasing capacity to increasing utilization of their existing systems. As of June 30, 2026, we had an Ion system installed base of approximately 1,096 systems, compared to approximately 905 systems as of June 30, 2025.

Ion System Placements - Europe

9

During the second quarter of 2026, 55 Ion systems were placed compared to 54 systems in the second quarter of 2025. By geography, 42 systems were placed in the U.S., 9 in Europe, 2 in Asia, and 2 in other geographic markets during the second quarter of 2026, compared to 47 systems placed in the U.S., 3 in Europe, 2 in Asia, and 2 in other geographic markets during the second quarter of 2025. In the U.S., where we estimate that Ion’s penetration of overall lung biopsy procedures has exceeded the halfway point, our customers’ focus has begun to shift from increasing capacity to increasing utilization of their existing systems. As of June 30, 2026, we had an Ion system installed base of approximately 1,096 systems, compared to approximately 905 systems as of June 30, 2025.

Ion System Placements - Other Geographic Markets

2

During the second quarter of 2026, 55 Ion systems were placed compared to 54 systems in the second quarter of 2025. By geography, 42 systems were placed in the U.S., 9 in Europe, 2 in Asia, and 2 in other geographic markets during the second quarter of 2026, compared to 47 systems placed in the U.S., 3 in Europe, 2 in Asia, and 2 in other geographic markets during the second quarter of 2025. In the U.S., where we estimate that Ion’s penetration of overall lung biopsy procedures has exceeded the halfway point, our customers’ focus has begun to shift from increasing capacity to increasing utilization of their existing systems. As of June 30, 2026, we had an Ion system installed base of approximately 1,096 systems, compared to approximately 905 systems as of June 30, 2025.

Ion System Placements - Outside U.S.

13

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Ion System Placements - Total

55

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Ion System Placements - U.S.

42

System Demand System placements are driven by procedure growth in most geographic markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci procedure adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. The following table summarizes our da Vinci and Ion placements during the periods presented (amounts shown in ones): Three Months Ended June 30, | | | Six Months Ended June 30, 2026 | | | 2025 | | | 2026 | | | 2025 Da Vinci Surgical System Placements by Region U.S. unit placements | | 267 | | | | 216 | | | | 493 | | | | 420 OUS unit placements | | 201 | | | | 179 | | | | 406 | | | | 342 Total unit placements (1) 468 | | | | 395 | | | | 899 | | | | 762 ________ (1) Includes the following number of units involving trade-ins: 144 | | | | 83 | | | | 263 | | | | 150 Ion System Placements by Region U.S. unit placements | | 42 | | | | 47 | | | | 81 | | | | 92 OUS unit placements | | 13 | | | | 7 | | | | 26 | | | | 11 Total unit placements 55 | | | | 54 | | | | 107 | | | | 103

Da Vinci Utilization Year-over-Year Growth

3.0%

• As of June 30, 2026, we had a da Vinci surgical system installed base of approximately 11,710 systems, an increase of 12% compared to an installed base of approximately 10,488 systems as of June 30, 2025. • Utilization of da Vinci surgical systems, measured in terms of procedures per system per year, increased 3% relative to the second quarter of 2025.